In this report, we developed a chimeric receptor (N29g chR) involving the single chain Fv (scFv) derived from N29 monoclonal antibody (mAb) specific for p185HER2 and characterized the therapeutic efficacy of primary T cells engineered to express N29g chR in two histologically distinct murine tumor models. Murine breast (MT901) and fibrosarcoma (MCA207) cancer cell lines were engineered to express human HER2 as targets. Administration of N29g chR-expressing T cells eliminated 3-day pulmonary micrometastases of MT901/HER2 and MCA207/HER2 but not parental tumor cells. A 5 to 8-fold increased dose of N29g T cells was required to mediate regression of advanced 8-day macrometastases. Exogenous administration of interleukin-2 (IL-2) after N29g T-cell transfer was dispensable for treatment of 3-day micrometastases, but was required for mediating regression of wellestablished 8-day macrometastases. Moreover, fractionated CD8 T cells expressing N29g chR suppressed HER2-positive tumor cell growth after adoptive transfer independent of CD4 þ cells. These data indicate that genetically modified T cells expressing a HER2-targeting chimeric receptor can mediate antigen-specific regression of preestablished metastatic cancers in a cell dose-dependent fashion. Systemic administration of IL-2 augments the therapeutic efficacy of these genetically engineered T cells in advanced diseases. These results are relevant to the implication of genetically redirected T cells in clinical cancer immunotherapy.
Introduction
Adoptive transfer of T lymphocytes accompanied by systemic administration of interleukin-2 (IL-2) has been effective in mediating tumor regression in both animal models and in human trials. [1] [2] [3] [4] [5] However, several obstacles limited its application. Tumors are resistant to T cellmediated immune responses by loss of cell surface major histocompatibility complex (MHC) expression [6] [7] [8] and downregulated tumor antigen processing. 9 On the other hand, the low frequency of tumor-specific T-cell precursors in a substantial proportion of patients hampers routine isolation of these cells, and therefore makes it difficult to generate large numbers of effector T lymphocytes with specific antitumor reactivity needed for adoptive transfer. 2 Consequently, 'targeted adoptive immunotherapy' or 'genetic adoptive immunotherapy' has become an attractive option for cancer treatment. This strategy can be approached in two different ways: introducing tumor-specific T-cell antigen receptor (TCR) into naive cells, or introducing a chimeric TCR (chTCR) into effector cells.
The cloning of functional TCRab complex genes capable of recognizing tumor antigens offers a potential opportunity to genetically modify naive T cells that have not been previously exposed to tumor. 10, 11 While genetic alteration of T cells with antigen-specific TCR genes confers the redirection of effector cells to the tumor, the recognition and the destruction of the latter still require the participation of MHC molecules. The alternative genetic approach to redirect T cells involves the introduction of a chimeric TCR into effector cells. This 'T-body' approach uses lymphocytes transfected with chimeric receptor genes constructed with a single chain variable domain of monoclonal antibodies (single chain Fv, scFv) linked to the constant regions of a signaling TCR-z chain or Fc-receptor-g chain. The rationale for this novel approach to redirect effector cells combines the effector functions of T lymphocytes with the ability of antibodies to recognize predefined surface antigens with high specificity in a non-MHC-restricted manner and independently of antigen processing.
In the course of adoptive immunotherapy of cancer, administration of T-cell growth factors accompanying T-cell transfer may promote T-cell activation, proliferation and tumor killing, and therefore augments clinical outcomes for the therapy. The most used adjuvant to T-cell transfer to date has been the exogenous administration of IL-2. 1, 5 However, the use of IL-2 has resulted in significant morbidity. 5, 12 Moreover, studies showed that IL-2 may negatively regulate effector cells through activation-induced cell death, 13 expanding the frequency of CD4 þ CD25 þ T cells, or cause cell redistribution secondary to Ag-induced cell death. 14, 15 On the other hand, the role of IL-2 in adoptive transfer of chTCRtransduced T cells is controversial. For example, primary T cells modified to express Fv-z receptor-recognizing tumor antigen on EL4 tumors significantly enhanced the antitumor activity in a murine EL4 lymphoma model, but the antitumor effect of Fv-z T cells was observed only in the presence of administrated IL-2. 16 In contrast, a separate study demonstrated that administration of exogenous IL-2 was not mandatory for the antitumor effect of chTCR-transferred T cells. 17 Therefore, the function of IL-2 in the antitumor activity mediated by adoptive transfer of chTCR-modified effector cells needs to be further defined.
In this study, we have developed an scFv chimeric receptor recognizing p185HER2 (N29g chR) to redirect T cells toward tumors that overexpress HER2. N29g chR-transduced primary murine splenic T cells induced antigen-specific regression of preestablished breast cancer and fibrosarcoma pulmonary micrometastases and macrometastases in a dose-dependent manner. Systemic administration of IL-2 augmented the therapeutic efficacy of these genetically engineered T cells in advanced diseases.
Materials and methods
Tumor cell lines MT901, a dimethylbenzanthracene-induced mammary tumor cell line, was derived from BALB/c mice. MCA207 murine tumor was 3-methylcholanthrene-induced fibrosarcoma syngeneic to C57BL/6 (B6) mice. The MT901/HER2 and MCA207/HER2 cell lines were constructed by retroviral transduction of cDNA encoding human HER2 into MT901 and MCA207 parental cells, respectively. Human ovarian adenocarcinoma cell line SKOV3 (no. HTB77) was obtained from the American Type Culture Collection (Rockville, MD). All the cell lines were cultured in complete medium composed of Dulbecco's modified Eagle's medium (high glucose, Gibco-BRL, Grand Island, NY) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (FBS; Gibco-BRL), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and 2 mM L-glutamine (Gibco-BRL).
Mice BALB/c and B6 mice were purchased from the National Cancer Institute and maintained in specific pathogen-free condition at the University of Michigan Animal Facility. All animal protocols were reviewed and approved by the University of Michigan Committee on Use and Care of Animals.
Flow cytometry
Antibodies utilized were phycoerythrin (PE)-conjugated antihuman HER2/neu (Neu 24.7, Becton Dickinson, San Jose, CA), fluorescein isothiocyanate-conjugated anti-mouse CD4 (L3T4, GK1.5, Pharmingen, Los Angeles, CA), PE-conjugated anti-mouse CD8a (Ly-2, Pharmingen) and Cy-chrome-conjugated anti-mouse CD3 (17A2, Pharmingen). Isotype-matching antibodies were used as controls. Cells were stained with conjugated monoclonal antibodies (mAbs) and analyzed using EPICS-XL flow cytometer and XL System II software (Beckman-Coulter). To quantitate expression of HER2 molecules per cell, standardized antibody-binding microbeads (Quantum Simply Cellular, Bangs Laboratories, Fishers, IN) were used. The background value of isotype control-stained cells was subtracted from the calculated density of HER2 to obtain the actual number of molecules per cell.
Immunohistochemistry
Immunohistochemical staining was performed using the Dako Autostainer (Dako, Carpinteria, CA) and Dako LSAB þ Peroxidase Kit and diaminobenzidine as the chromogen. Deparaffinized sections of formalin-fixed tissue at 5 mm thickness were stained with hematoxylin and eosin or labeled with HER2 (Rabbit polyclonal antibody, Dako, 1:100). Appropriate negative (no primary antibody) and positive controls (HER2 overexpressing breast carcinoma) and normal murine lungs (no pulmonary metastases) were stained in parallel with each set of pulmonary metastases examined. Digital photomicrographs were obtained at Â 200 magnification.
T-cell purification and activation
Murine spleens were removed, mechanically homogenized and filtered through a 70 mm nylon cell strainer (Fisher Scientific, Pittsburgh, PA). Erythrocytes were lysed with ACK lysing buffer (150 mM NH 4 Cl, 1 mM KHCO 3 and 0.001 mM EDTA), and the single-cell suspension was washed in RPMI 1640 medium supplemented with 10% (vol/vol) heat-inactivated FBS, 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and 2 mM L-glutamine (Gibco-BRL) (complete RPMI medium). T cells were enriched by negative selection over sterile brushed nylon wool fiber (Polysciences Inc., Warrington, PA). Nonadherent T cells were eluted with warm RPMI 1640 medium after a 45-min absorption period. T cells were activated by culture with immobilized purified anti-mouse CD3 (BD Pharmingen) and anti-mouse CD28 (BD Pharmingen).
Briefly, each antibody was diluted in phosphate-buffered saline (PBS) at a final concentration of 2 mg ml
À1
. Twentyfour-well plates (Costar, Cambridge, MA) were coated with 600 ml of combination of anti-mouse CD3/CD28 (each 1.2 mg per well) at 4 1C overnight, then washed twice with PBS. T cells were placed in plates (4 Â 106 per well in 2 ml of complete RPMI 1640 medium) and cultured in a 5% CO 2 -humidified incubator at 37 1C for 48 h. The activated T cells were expanded in complete RPMI 1640 medium containing 300 IU ml À1 rhIL-2 (Chiron Corporation, Emeryville, CA) at a starting concentration of 1 Â 10 6 per ml in six-well culture plates (Costar) for another 48 h before T-cell transduction.
Retroviral vectors and producer cells
An scFv derived from the N29 mAb, 18, 19 which binds an extracellular epitope of p185 HER2, served as the antigen recognition domain of the recombinant receptor. The N29 scFv was directly coupled to the FceRI g-chain to form the N29g chR. A retroviral vector expressing the N29g receptor was constructed in pRET6, a bicistronic retroviral backbone developed in our laboratory. pRET6.GFP (green fluorescence protein) was constructed as a control. Ecotropic producer cell lines were generated with standard techniques in GP þ E86 cells, a kind gift from Dr Arthur Bank, Columbia University. Supernatant from the polyclonal producer cells had a viral titer of 5-10 Â 10 5 c.f.u. per ml and were free of replication competent virus.
T-cell transduction
Activated and expanded T cells were transduced with recombinant retrovirus in plates precoated with Retronectin (Takara Shuzo Co., Shiga, Japan). Nontissue culture-treated 24-well plates were coated with Retronectin (40 mg in 0.5 ml PBS per well) at 4 1C overnight, blocked with 2% bovine serum albumin (Sigma-Aldrich, St Louis, MO) in PBS at room temperature for 30 min, and washed twice with 2.5% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid prior to use. Activated T cells were resuspended in filtered retroviral supernatant at a concentration of 1-2 Â 10 6 per ml, and loaded onto Retronectin-coated plates (2 ml per well) and centrifuged (1300 g) for 90 min at 32 1C. Subsequently, the supernatant was removed and replaced with fresh complete RPMI 1640 medium supplemented with rhIL-2 (300 IU ml À1 ). After culture for 24 h in the Retronectincoated plates, the transduced cells were recovered and expanded in complete RPMI medium plus rhIL-2 (1 Â 10 6 cells per ml) on six-well plates for 48 h prior to adoptive transfer. Retroviral transduction efficiency of T cells was B40-50%, which was indirectly determined by GFP expression of T cells using flow cytometry. We made three vectors: pRET6.GFP, pRET6.N29g and pRET6. GFP.N29g. In our pre-experiments, we found that pRET6.GFP and pRET6.GFP.N29g transduced T cells both at the transduction rate of 40-50% by gating on GFP þ T cells. This allowed us to anticipate a similar transduction rate when pRET6.N29g was used under the identical transduction condition. Functionally, similar antitumor effects of pRET6.N29g and pRET6. GFP.N29g-transduced T cells on pulmonary metastases were observed. Therefore, pRET6.GFP and pRET6.N29g were used in most of our experiments as control and as the treatment group, respectively. heparin. T-cell suspension (1 ml) was injected per mouse through tail vein. IL-2, if used, was administrated by peritoneal injection at a dose of 30 000 IU or otherwise indicated every 12 h for 5 days after T-cell adoptive transfer. Lungs were harvested 14 or 21 days after tumor cell injection and pulmonary tumor nodules were enumerated after staining with India Ink (Higgins, Bellwood, IL).
Adoptive immunotherapy of pulmonary metastasis

Assessment of cytokine release
Nontransduced and unselected populations of GFP-or N29g chR-transduced T cells were co-cultured with tumor cell lines overexpressing HER2 (SK-OV-3) or not expressing HER2 (MCF7) for 24 h. The supernatant of co-culture was then collected and analyzed for interferon-g (IFNg) secretion using commercially available enzyme-linked immunosorbent assay (ELISA) kits (Pharmingen).
T-cell fractionation CD4
þ or CD8 þ cells were enriched from retrovirustransduced T cells by negative selection. Briefly, transduced T cells were incubated with anti-mouse CD4 (L3T4) or anti-mouse CD8a (Ly-2) antibody-conjugated superparamagnetic microbeads (Miltenyi Biotec Inc., Sunnyvale, CA) for 30 min and then loaded onto MACS separation column (Miltenyi Biotec Inc.) in the magnetic field of a MACS separator. The purity of CD4 þ and CD8 þ T cells after fractionation was 485% and approximately 90%, respectively as shown by flow cytometry.
Statistical analyses
The significant differences of numbers of pulmonary metastases between experimental groups were determined by t-test. Two-side Po0.05 was considered statistically significant.
Results
Specific regression of MT901/HER2 and MCA207/HER2 pulmonary metastases mediated by T cells expressing the N29g chR A subline of MT901 was engineered to express human HER2 and to serve as the target for T cells expressing N29g chR. The clone expressing the highest level of HER2, as demonstrated by flow cytometry (Figures 1a and b), was chosen for subsequent experiments. Furthermore, to determine the intensity of HER2 molecules on the surface of engineered MT901/HER2 cells, a regression equation: Y ¼ 10354XÀ7373.1 was used (Y, intensity of molecules per cell; X, mean fluorescence intensity). The calculation was based on the relationship between the mean fluorescence intensity of mAb-labeled microbeads and standard antibody-binding capacity of these microbeads. We found that the intensities of HER2 expression on the surface of SKOV3, parental MT901 and MT901/ HER2 were 9 179 85, 0 and 1 237 520 molecules per cell, respectively. To determine HER2 expression in vivo, lungs from mice bearing 8-day pulmonary metastases of MT901/HER2 or parental MT901 (as control) were fixed, sectioned and stained. HER2 expression was not found in pulmonary metastases of parental MT901 by immunohistochemistry (Figure 1c ), but quantified grade 3 þ staining was seen in lung metastases of MT901/HER2 ( Figure 1d ).
To define the therapeutic potential of genetically modified T cells expressing the N29g chR, we developed tumor models of adoptive immunotherapy in immunocompetent mice.
Mice bearing 3-day MT901 or MT901/HER2 pulmonary micrometastases were randomized (n ¼ 5 per group) into following groups: mock treatment (no T cells, no IL-2), IL-2 alone (IL-2 group), nontransduced T cells, GFPtransduced T cells, both GFP and N29g chR-transduced T cells, or N29g chR-transduced T cells. As shown in Figure 2a , more than 250 metastases were present in lungs from mice in the mock-and IL-2-treated groups. Nontransduced parental T cells or GFP-modified T cells failed to eliminate either parental or HER2-positive MT901 tumor metastases. Confluent (4250) lung metastases were seen in mice bearing HER2-negative parental MT901 tumor metastases regardless of the treatment regiments. However, treatment of mice bearing HER2-positive tumor with 5 Â 10 6 N29g/GFP T cells or N29g T cells resulted in significant clearance of the tumor (Po0.01 compared to the parental tumor).
We also performed in vitro immune function assays to show the tumor reactivity of N29g chR-transduced T cells in response to HER2. As shown in Figure 2b , while To verify the therapeutic potential of genetically modified T cells expressing the N29g chR in histologically distinct tumor models and different host strains, we used the MCA207 tumors in C57BL/6 mice in the subsequent experiments. As in the previous studies, paired cohorts of animals received i.v. injections of either parental (HER2-negative) MCA207 tumor cells, or a subline of MCA207 genetically engineered to stably express human HER2 (MCA207/HER2) to determine if adoptive transfer of the syngeneic host-derived and genetically modified T cells could eliminate preestablished pulmonary metastases. As shown in Table 1 , 3 days after tumor inoculation, paired cohorts of mice were injected i.v. with retrovirally transduced murine T cells (5 Â 10 6 cells per mouse) expressing N29g chR or GFP (control). All mice received rhIL-2 administration and were killed 14 days after tumor cell injection for lung metastasis enumeration as in the MT901 studies. More than 250 metastases were present in lungs from animals injected with the HER2-negative parental MCA207 tumor cell line, irrespective of the T-cell therapy. While GFP-modified T cells failed to eliminate HER2 þ metastases, treatment of animals bearing HER2-positive tumors with T cells expressing the N29g chR resulted in clearance of nearly all the tumors (Po0.01) in two of the two experiments performed.
Collectively, these experiments indicate that T cells armed with the N29g chR to recognize HER2 antigen can specifically mediate effective regression of HER2-expressing tumors in adoptive transfer.
N29g chR-expressing T cells mediate HER2-specific elimination of pulmonary micrometastases and macrometastases in a dose-dependent manner We proceeded by examining the dose requirement in eliminating the MCA207/HER2 pulmonary micrometastases by adoptively transferred N29g chR-expressing T cells. C57BL/6 mice bearing 3-day MCA 207/HER2 pulmonary micrometastases were randomized to receive genetically modified T cells expressing GFP or N29g chR at various doses as indicated. Mice were killed 14 days after tumor cell injection to quantitate the mean number of lung nodules in each group. As shown in Figure 3 
Abbreviation: GFP, green fluorescence protein.
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antitumor effect of N29g chR-transduced T cells was dropped with the descent of the T-cell dose infused. We next determine whether T cells expressing N29g chR were able to mediate regression of more advanced pulmonary macrometastases. Mice bearing 8-day MT901 or MT901/HER2 pulmonary metastases were randomized (n ¼ 5 per group) to receive genetically modified T cells expressing N29g chR at various doses range from 1 to 4 Â 10 7 cells per mouse. Control mice received T cells expressing GFP at the highest dosage used or PBS only (mock). All mice were injected intraperitoneally (i.p.) with 30 000 IU rhIL-2 twice a day for 5 days following T-cell adoptive transfer. Mice were killed 21 days after tumor challenge to enumerate the pulmonary metastases. As indicated in Table 2 , more than 250 lung metastases were present in lungs from mice bearing parental MT901, irrespective of treatment. More than 250 pulmonary metastases were also present in lungs from mice bearing MT901/HER2 that were treated with PBS (mock) or GFP-modified T cells. Nonetheless, treatment with N29g-modified T cells showed a cell dose-dependent effect on HER2 þ lung metastases. While 1 Â 10 7 N29g T cells were not enough to mediate significant reduction of lung metastases (167 ± 15, P ¼ 0.198 compared to parental MT901 T cells), increased dosage of N29g-modified T cells at 2, 3 or 4 Â 10 7 decreased the number of pulmonary metastases to 64 ± 12, 34 ± 6 and 8 ± 4, respectively.
Together, these data support the conclusion that N29g chR T cells can mediate HER2-specific elimination of both micrometastases and macrometastases in a cell dose-dependent manner.
Divergent requirement of exogenous IL-2 during N29g chR T cell-mediated tumor regression
Systemic administration of IL-2 has not only served as a useful component in adoptive T-cell therapy of cancer, but also resulted in significant toxicity. 20 It is therefore important to determine the requirement of systemic administration of IL-2 in adoptive immunotherapy using N29g chR-expressing T cells. Initially, mice bearing 3-day MT901/HER2 pulmonary micrometastases were tested. Tumor-bearing hosts received 8 Â 10 6 N29g T cells or GFP T cells per mouse. Each cohort was further randomized with or without IL-2 administration. As shown in Figure 4a , confluent lung metastases were present in mice injected with GFP T cells either with or without IL-2 administration. Treatment of mice with N29g T cells plus IL-2 resulted in total clearance of pulmonary metastases. Of note, very few (o5) lung metastases were found in the lungs of mice treated with an equal number of N29g T cells without IL-2 administration. These experiments thus indicate that T cells expressing N29g chR could mediate regression of pulmonary micrometastases independently of IL-2.
We next examined if systemic administration of IL-2 is required for N29g chR-expressing T cells to mediate regression of pulmonary macrometastases. Mice bearing 8-day MT901/HER2 pulmonary metastases were randomized to receive 40 Â 10 6 N29g T cells or GFP T cells per mouse. Each cohort was then randomized with or without IL-2 administration. As revealed in Figure 4b , more than 250 lung metastases were present in mice infused with GFP T cells regardless of IL-2 administration. Very few (6 ± 4) pulmonary metastases were left in the lungs of the mice treated with N29g-transduced T cells plus IL-2. However, in contrast to the previously described micrometastatic models, N29g-transduced T cells alone were unable to inhibit macrometastases without the administration of IL-2. These studies suggest that IL-2 was required for the genetically modified T cells to mediate regression of well-established pulmonary tumors.
To determine if we could preserve the antitumor effect of N29g T cells with low dose of IL-2 to reduce the potential toxicity of IL-2, various doses of IL-2 were Abbreviations: GFP, green fluorescence protein; PBS, phosphate-buffered saline. n ¼ 5, five mice each group. Po0.01 compared to mice bearing HER2-negative parental MT901 treated with the same dose of T cells.
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tested during the adoptive T-cell therapy of wellestablished pulmonary macrometastases. Mice bearing 8-day MT901/HER2 pulmonary metastases were treated with N29g T cells at 4 Â 10 7 cells per mouse as previously, but received various dosages of systemically administrated IL-2. As demonstrated in Figure 5 , at low doses of IL-2 (0-5 Â 10 3 ), antigen-specific T cells showed now therapeutic efficacy. However, at higher dosages of IL-2 (15 Â 10 3 or 30 Â 10 3 IU), the same T cells reduced the tumor metastases significantly to 10±3 and 8±2, respectively. These experiments suggest that exogenous administration of IL-2 may need to reach a threshold value before adoptively transferred N29g T cells could mediate effective regression of well-established pulmonary macrometastases.
CD8
þ N29g T cells could mediate tumor regression independently of CD4 þ cells In all of the previous experiments, unfractionated T cells were used in adoptive transfer. Unfractionated T cells were composed of both CD4 and CD8 T cells, and similar transduction efficiency of CD4 and CD8 cells was achieved as indicated by flow cytometry (data not showed). The frequency of CD4 and CD8 cells in the unfractionated and N29g-transduced T cells was approximately 40 and 55%, respectively. To determine the roles played by N29g chR-expressing CD4 and CD8 T cells respectively in antitumor effect, we enriched CD4 þ and CD8 þ cells by negative selection prior to adoptive transfer. Mice bearing 8-day MT901/HER2 pulmonary metastases were randomized to receive treatment with unfractionated N29g T cells ( þ T cells and CD8 þ T cells (2 Â 10 7 each cells per mouse) (n ¼ 5 per group). As illustrated in Figure 6 , unfractionated T cells plus IL-2 suppressed tumor growth effectively (11 ± 3 metastases per lung), which served as a positive control in these experiments. Fascinatingly, enriched CD8 þ T cells alone revealed a similar capability to eliminate the pulmonary metastases (13 ± 1 metastases per lung), and so did the mixture of enriched CD4 þ and CD8 þ T cells (16 ± 2 metastases per Each cohort was further randomized to receive either no systemic IL-2 or IL-2 at a dose of 30 000 IU twice a day for 5 days. Mice were killed 14 days after tumor injection to enumerate pulmonary metastases (n ¼ 5 per group). *Po0.001 compared to mice received GFP-transduced T cells with or without systemic IL-2 administration. Data are representative of three independently performed experiments. (b) Administration of IL-2 is required for T cells expressing N29g chR to mediate the regression of pulmonary macrometastases. Mice bearing 8-day MT901/HER2 pulmonary macrometastases were randomized to receive treatment with GFP or N29g T cells at 4 Â 10 7 cells per mouse. Each cohort was further randomized to receive no systemic IL-2 or IL-2 administration at a dose of 30 000 IU twice a day for 5 days. Mice were killed 21 days after tumor injection to enumerate pulmonary metastases (n ¼ 5 per group). *Po0.001 compared with any other groups. These results were repeated in three independently performed experiments. HER2-targeted T-cell therapy of cancer S Li et al lung). However, enriched CD4 þ T cells showed no impact on the pulmonary metastases (4250 metastases per lung). These results thus indicate that N29g chRexpressing CD8 T cells could mediate tumor regression independently, and may therefore play a fundamental role in mediating tumor regression in a setting exploited in this study.
Discussion
The difficulties in obtaining large numbers of tumorspecific T cells as well as the divergent distribution of the effector cells after infusion have limited the successful application of cancer immunotherapy using adoptively transferred T cells. A promising procedure employed to circumvent the defect of antibody in antitumor response is to combine its tumor antigen-specific recognition capability with direct cellular cytotoxicity of effector T cells. To this end, various recombinant TCRs have been constructed to fight against cancer. 17, 21, 22 Retroviral transduction of the anti-TNP (trinitrophenyl)/TCR chimeric gene into a T-cell hybridoma line resulted in cytolytic activity and release of IL-2 in response to TNPlabeled target cells, but not to unlabeled cells. 23 Hwu et al. 21, 24 developed a recombinant chimeric receptor against an epitope expressed on the ovarian cancer cell lines. Pinthus et al. 25 evaluated the therapeutic efficacy of anti-erbB2 chimeric receptor-bearing human lymphocytes on human prostate cancer xenografts in a severe combined immunodeficiency mouse model. A separate study demonstrated prostate-specific membrane antigentargeted elimination of prostate cancer by genetically directed human peripheral blood T cells. 26 In a setting of metastatic cancer, 27 anti-erbB-2 (clone 9G6.10) chimeric receptor-modified T cells killed breast cancer cells in an Ag-specific manner. To redirect effector lymphocytes to adenocarcinomas, Stancovski et al. 18 functionally expressed chimeric single chain receptor genes incorporating the Ag-binding domain of anti-Neu/HER2 antibodies in T cells. Surface expression of the antiNeu/HER2 chimeric genes in cytotoxic T-cell hybridomas endowed them with specific Neu/HER2 recognition, for example, activation for IL-2 production and lysis of Neu/ HER2-expressing cells. However, no in vivo experiments were performed to examine the therapeutic efficacy of these genetically modified effector cells. In this study, we coupled a scFv of anti-185HER2 mAb N29, to the FceRI g-chain to form the N29g chR. Splenocytes isolated from the syngeneic hosts and enforced to express the N29g chR effectively mediated HER2-specific tumor regression of preestablished micrometastases as well as macrometastases in two histologically distinct tumor models.
The HER2/neu proto-oncogene encodes a 185 kDa transmembrane protein receptor with tyrosine kinase activity. 28 Overexpression of HER2/neu is identified in approximately 30% of breast and ovarian cancer and correlated to poor prognosis. Administration of antibody targeting at HER2 resulted in growth inhibition of HER2-expressing tumor in experimental and clinical trials. 29, 30 These findings suggested that p185HER2 is an excellent potential target for immune-based therapy of cancer. We found that T cells expressing N29g chR specifically recognized HER2-positive tumor cells in vitro and resulted in cytokine secretion (Figure 2b ). More importantly, N29g T cells efficiently mediated regression of pulmonary metastases of MT901/HER2 breast cancer and MCA207/HER2 sarcoma in vivo, and the efficacy of N29g T cells in mediating regression of HER2-specific tumors is cell dose dependent. Significantly more tumor antigen-specific T cells are required to eliminate larger tumors.
We compared the antitumor effect of N29g chR transgenic T cells with HER2-specific T cells (data not shown). BALB/c mice bearing 3-day MT901/HER2 pulmonary metastases were killed. Spleen T cells were purified, expanded with rIL-2 and served as HER2-specific T cells. Spleen T cells purified from no tumorbearing BALB/c mice were transduced with N29g chR. HER2-specific T cells and N29g chR transgenic T cells were administrated to 3-day MT901/HER2-bearing BALB/c mice. Pulmonary metastases were counted 14 days after T-cell transfusion. T cells from no tumorbearing mice with no chimeric receptor transduction were used as mock group. Although HER2-specific T cells showed antitumor effect to certain extent compared to mock group (pulmonary metastases were 220±10 vs 4250, P ¼ 0.024), the significant difference of antitumor effect was observed between HER2-specific and chimeric receptor-transduced T cells (pulmonary metastases HER2-targeted T-cell therapy of cancer S Li et al 220±10 vs 8±4, P ¼ 0.015). The results may suggest that N29g chR-expressing T cells had stronger antitumor effect than regular tumor antigen-specific T cells. However, these experiments do not exclude the use of TCR by the T cells armed with N29g chR, even though other studies have provided evidence that T cells expressing a chimeric receptor can protect hosts from pathogens through TCR-independent yet pathogen-specific receptors. 31 In our study, splenocytes isolated from MT901/ HER2 tumor-bearing host may not represent an optimal source of HER2-specific T cells. An ideal comparison between N29g chR transgenic and HER2-specific T cells 32 should involve the constriction of N29-TCR chR by directly coupling the N29scFv to the TCR, and then compare the proliferation and in vitro and in vivo antitumor activity of the N29g chR transgenic T cells with such N29-TCR chR transgenic T cells.
N29g T cells completely eliminated the pulmonary metastases of MT901/HER2 tumor in the 3-day micrometastasis model without IL-2. However, in the 8-day macrometastasis model, N29g T cells inhibited tumor growth only in the presence of IL-2. Apparently, while IL-2 was dispensable during T-cell regression of early, small tumors, it was required to support N29g T cells to eliminate more advanced larger tumors. In addition, our titration experiments indicated that IL-2 needs to reach a threshold value to support the maximal T-cell activity. This information may help determine the minimal dose of IL-2 required while using gene-modified T cells for cancer therapy.
After adoptive transfer, persistence, trafficking and the formation of memory T cells are critical factors determining the therapeutic efficacy of the genetically modified T cells. 33, 34 We reported that adoptively transferred T cells infiltrated pulmonary tumor nodules and eradicated established tumor metastases. 35 Using MHC class I-restricted TCR transgenic T cells from the OT-1 mouse, which are specific for the surrogate tumor Ag ovalbumin, our group also found that exogenous IL-2 promoted T-cell persistence after adoptive transfer, and donor CD8 þ T cells developed a memory phenotype based on CD44 and Ly6c expression. 36 In this study, we did not examine if the expression of the novel receptor N29g chR influences the fate of the transduced T cells in vivo. Such studies would help understand the mechanisms involved in transduced T cell-mediated tumor regression and the potential induction of systemic immunity and long-term antitumor responses.
We observed in this study that CD8 þ N29g T cells could mediate HER2-positive tumor regression independently. CD8 þ cytotoxic T lymphocytes have long been recognized as the effector cells that mediate tumor regression. In addition, CD4 þ effector T cells, natural killer (NK) cells have also been identified to directly or indirectly mediate tumor regression. [37] [38] [39] In general, help provided by CD4 þ cells is needed for CD8 þ cell activation and function. 40, 41 An advantage of using chimeric TCR-transfected T cells is the direct targeting/ recognition of tumor antigen on tumor cells by the antibody portion of the TCR without MHC restriction and antigen processing. This advantage makes it possible that CD8 þ effector cells may mediate immune response in vivo in the absence of CD4 þ cell help. Alternatively, CD8
þ cells may function with the help provided by themselves. This possibility remains to be elucidated in our study. On the other hand, Hombach et al. 42 reported that CD4 þ cells isolated from the peripheral blood and engrafted with a recombinant immunoreceptor specific for carcinoembryonic Ag efficiently lysed target cells in an MHC-independent fashion, and the efficiency was similar to that of grafted CD8 þ T cells. However, in our study, enriched transgenic CD4 þ T cells showed no impact on the HER2-expressing pulmonary metastases. Successful T-cell therapy should include the identification of T-cell subsets responsible for mediating antitumor reactivity as well as the elimination of those subsets that are nonreactive or even suppressive. 43 Characterization of regulatory CD4
þ CD25 þ T-cell subpopulation in terms of their potential suppressive effects on genetically modified anticancer effector T cells would warrant further investigations.
Elevated soluble HER2 protein levels in the serum of tumor-bearing animals or cancer patients may affect the therapeutic efficacy of any strategies targeting HER2-expressed tumor cells. For example, in a study with HER2-specific antibody therapy in patients bearing HER2-expressed tumors, the higher soluble HER2 level was found to be correlated with a decreased therapeutic efficacy of administrated HER2-specific antibody. 44 This may be due to the formation of antigen-antibody complex in the serum, followed by the clearance of the complex from the circulation. Similarly, soluble HER2 may block the targeting of HER2-expressing tumor cells by the constructed N29g chR T cells through binding to these receptors on T cells. We have not tested such possible affect of soluble HER2 in this study, but believe that this reminds as an important issue for further evaluation on the application of N29g chR-transduced T cells.
Targeted adoptive immunotherapy by introducing a chimeric TCR into effector cells is one of the fast developing areas in cancer treatment. In addition to antibody-antigen interaction, receptor-ligand interaction has also been used for the construction of chimeric T-cell receptors. For example, linking human NKG2D to the CD3z chain generated a chimeric NKG2D receptor that allowed activation of primary human T cells on engagement with NKG2D ligand-positive tumor cells. 45 These approaches may offer novel opportunities to develop immunocompetent effector cellular reagents and improve the efficacy of adoptive immunotherapy of cancer.
